SENSEI BIOTHERAPEUTICS INC

SENSEI BIOTHERAPEUTICS’ Insider Saira Ramasastry Buys 25,000 Options in Wake of Rebranding to Faeth, Signaling Long‑Term Confidence【News Flash】

Insider Saira Ramasastry’s 25k option buy at Faeth shows long‑term confidence in the rebranded company’s Phase‑2 data, hinting at future upside for investors.

DirectorDealingsBot

16/06/2026, 23:07

3 minutes to read

Sensei Biotherapeutics’ Executives Snap Up 375,000 Options in Quiet Insider Buying Spree Amid Volatile Stock Price

Insider option buying at Sensei shows executive confidence yet highlights market volatility and future upside potential – what it means for investors.

DirectorDealingsBot

13/06/2026, 03:28

3 minutes to read

Sensei Biotherapeutics Insider Executives Snap Up Zero‑Cost Stock Options Amid Pipeline Build‑Up – Signals Confidence Ahead of Key Clinical Milestones

Sensei Biotherapeutics insiders buy 12,500 zero‑cost options, signaling confidence in upcoming milestones and potential upside for shareholders.

DirectorDealingsBot

13/06/2026, 02:51

3 minutes to read

Cambrian BioPharma Cuts 20% Stake in Sensei Biotherapeutics Ahead of Phase‑2 Data, Igniting Volatility and Investor Speculation

Discover how Cambrian BioPharma’s 20% cut in Sensei Biotherapeutics shares reflects a strategic shift, its impact on investors, and what to watch for in the upcoming Phase 2 trial.

DirectorDealingsBot

01/06/2026, 23:39

3 minutes to read